medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2022, Número 3

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (3)


Riesgo de complicaciones virales postrasplante en candidatos a trasplante renal con donante vivo

Marcell RL, Costales ED, Morera BLM, Chang MA

Idioma: Español
Referencias bibliográficas: 41
Paginas: 1-10
Archivo PDF: 533.96 Kb.


RESUMEN

Introducción: El trasplante renal con donante vivo se promueve en Cuba y en el resto del mundo. La definición del riesgo de complicaciones postrasplante por citomegalovirus (CMV) y virus de Epstein Barr (EBV) es parte de las pruebas de compatibilidad pretrasplante.
Objetivo: Determinar el riesgo de complicaciones postrasplante con estos virus en pacientes cubanos candidatos a trasplante renal con donante vivo.
Método: Se determinaron anticuerpos IgG anti-CMV e IgG anti-EBV por ensayo de inmunoabsorción ligado a enzima en 301 muestras de candidatos a TRDV y 390 de posibles donantes recibidas, entre julio de 2013 y julio de 2019, en el laboratorio de Histocompatibilidad del Instituto de Hematología e Inmunología.
vResultados: En los candidatos a trasplante renal con donante vivo la seroprevalencia del EBV fue mayor que la del CMV y ambas aumentaron con la edad. El 100 % de los pacientes de grupo sanguíneo AB tuvieron EBV y CMV. No existió dependencia entre los anticuerpos anti-EBV y anti-CMV con los anticuerpos anti-HLA, la edad, sexo, color de la piel, grupo sanguíneo, hepatitis B y C, tipo de diálisis, trasplantes y transfusiones previas. El 7,3 % de los pacientes presentaron alto riesgo de complicaciones postrasplante.
Conclusiones: La seroprevalencia de CMV y EBV en los candidatos a trasplante renal con donante vivo cubanos es alta, por lo que pocos tienen riesgo alto de complicaciones postrasplantes debido a estos virus.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Villafuerte-Ledesma HM, De Sousa-Amorim E, Peri L, Musquera M, Palou E, Lozano M, et al1. . Impact of Discards for Living Donor Kidney Transplantation in a Transplant Program. Transplant Proc. 2019;51(10):3222-6.DOI: https:// 10.1016/j.transproceed.2019.09.008

  2. Kaya B, Erturk D, Paydas S, Demir E, Balal M, Gocum H. Evaluation of Living Kidney Donor and Recipient Candidates: The Experience of Our Center. Transplant Proc. 2019;51(7):2205-9. DOI: https:// 10.1016/j.transproceed.2019.04.071

  3. Valdivia-Arencibia J, Gutiérrez-Gutiérrez C, Méndez-Felipe D, Delgado-Almora E, Treto-Ramírez J, Fernández-Maderos I. Supervivencia en pacientes con trasplante renal. Factores pronósticos. Invest Medico quir. 2013;5(2):253-75.

  4. Marcell-Rodríguez L, Núñez-Gómez M, Morera-Barrios LM, Bencomo-Hernández A, ChangMonteagudo A, Ustariz-García C Caracterización de los anticuerpos anti-HLA en receptores de trasplante renal de donante vivo relacionado. Rev Cubana Hematol Inmunol Hemoter 2017;33(S1) [acceso 04/02/2022] Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/759 4.

  5. Marcell Rodríguez L, Morera Barrios LM, Costales Elizalde DT, Chang Monteagudo A, Ustariz García C, Bencomo Hernández A Anticuerpos anticitomegalovirus y antivirus de Epstein Barr pretrasplante renal en Cuba. Rev Cubana Hematol Inmunol Hemoter. 2016;32(4) [acceso 04/02/22]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/4635.

  6. Pretagostini R, Poli L, Lai Q, Russo G, Nudo F, Garofalo M, et al6. . Pre-Emptive Therapy for the Treatment of Cytomegalovirus After Kidney Transplantation. Transplant Proc. 2017;49(4):638-41. DOI: https:// 10.1016/j.transproceed.2017.02.019

  7. Parajuli S, Muth BL, Turk JA, Astor BC, Mohammed M, Mandelbrot DA, et al7. . In Kidney Transplant Recipients with a Positive Virtual Crossmatch, High PRA was Associated With Lower Incidence of Viral Infections. Transplantation. 2016;100(3):655-61. DOI: https:// 10.1097/tp.0000000000001061

  8. Costales Elizalde D, Morera Barrios LM, González García N, Chang Monteagudo A, Marcell Rodríguez L, Ustariz García CR, et al8. . Anticuerpos anticitomegalovirus y antivirus de Epstein Barr en pacientes cubanos en espera de trasplante hematopoyético. Rev Cubana Hematol Inmunol Hemoter 2017;33:1-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892017000200011&nrm=iso8.

  9. Babazadeh A, Javanian M, Oliaei F, Akbari R, Akbarzadepasha A, Bijani A, et al9. . Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran. Caspian J Intern Med. 2017;8(1):23-9. PMID: 28503279.

  10. Chang PY, Chien LN, Lin YF, Wu MS, Chiu WT, Chiou HY. Risk factors of gender for renal progression in patients with early chronic kidney disease. Medicine(Baltimore). 2016;95(30):e4203. DOI: https:// 10.1097/md.0000000000004203

  11. Kazancioğlu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl (2011). 2013;3(4):368-71. DOI: https:// 10.1038/kisup.2013.70

  12. Sentell T, Choi SY, Ching L, Quensell M, Keliikoa LB, Corriveau É, et al12. . Prevalence of Selected Chronic Conditions Among Children, Adolescents, and Young Adults in Acute Care Settings in Hawai'i. Prev Chronic Dis. 2020;17:E67. DOI: https:// 10.5888/pcd17.190448

  13. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle Factors, Obesity and the Risk of Chronic Kidney Disease. Epidemiology. 2003;14(4):479-87. DOI: https:// 10.1097/01.EDE.0000071413.55296.c4

  14. Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230-40. DOI: https:// 10.1038/nrcardio.2017.154

  15. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet2017;389:1238-52. DOI: https:// 10.1016/S0140-6736(16)32064-5

  16. Hounkpatin HO, Fraser SDS, Honney R, Dreyer G, Brettle A, Roderick PJ. Ethnic minority disparities in progression and mortality of pre-dialysis chronic kidney disease: a systematic scoping review. BMC Nephrology. 2020;21(1):217. DOI: https:// 10.1186/s12882-020-01852-3

  17. Morera Barrios LM, Chang Monteagudo A, García García MdA, de la Guardia O, Ustariz García C, Marcell Rodriguez L, et al17. . Frecuencia de genes HLA en pacientes con insuficiencia renal crónica procedentes del occidente y centro de Cuba. Rev Cubana Hematol Inmunol Hemoter 2015;31:32-40. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892015000100004&nrm=iso17.

  18. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al18. . Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034. DOI: https:// 10.1002/rmv.2034

  19. Fourcade G, Germi R, Guerber F, Lupo J, Baccard M, Seigneurin A, et al. Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000-2016. PLoS One. 2017;12(4):e0175574.doi:10.1371/journal.pone.0175574

  20. Kuri A, Jacobs BM, Vickaryous N, Pakpoor J, Middeldorp J, Giovannoni G, et al20. . Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 2020;20(1):912. DOI: https:// 10.1186/s12889-020-09049-X

  21. Farid E, Al-Biltagi M. Trend and seroprevalence of Epstein-Barr virus in Bahrain: 2001-2015. East Mediterr Health J. 2018;23(12):821-9. DOI: https:// 10.26719/2017.23.12.821

  22. Beader N, Kolarić B, Slačanac D, Tabain I, Vilibić-Čavlek T. Seroepidemiological study of Epstein-Barr virus in different population groups in Croatia. Isr Med Assoc J. 2018;20(2):86-90.Disponible en: https://www.ima.org.il/FilesUploadPublic/IMAJ/0/272/136222.pdf22.

  23. Mahmood R, Malik F, Hussain S, Ashfaq K, Akhtar T, Alam MR, et al23. . Seroprevalence of cytomegalovirus among blood donors in local population. Int J Pharm Chem 2014;4:146-50. DOI: https:// 10.7439/ijpc

  24. Varga M, Görög D, Kári D, Környei E, Kis É, Túryné HJ, et al24. . Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group. Transplant Proc. 2011;43(4):1233-5. DOI: https:// 10.1016/j.transproceed.2011.03.067

  25. Tiguman GMB, Poll LB, Alves CEC, Pontes GS, Silva MT, Galvao TF. Seroprevalence of cytomegalovirus and its coinfection with Epstein-Barr virus in adult residents from Manaus: a population-based study. Rev Soc Bras Med Trop. 2020;53:e20190363. DOI: https:// 10.1590/0037-8682-0363-2019

  26. Samiei RN, Mahmoudvand S, Shokri S, Makvandi M, Shahbazian H, Pirmoradi R, et al26. . The frequency of Epstein-Barr virus among hemodialysis patients, Ahvaz, Iran. Iran J Microbiol. 2019;11(1):75-9. DOI: https:// 10.18502/ijm.v11i1.709

  27. Berntsson M, Dubicanac L, Tunbäck P, Ellström A, Löwhagen GB, Bergström T. Frequent detection of cytomegalovirus and Epstein-Barr virus in cervical secretions from healthy young women. Acta Obstet Gynecol Scand. 2013;92(6):706-10. DOI: https:// 10.1111/aogs.12134

  28. Taie AA, Ibraheem MA, Fadhil KB. Epstein-barr virus infection in thalassemia patients related to blood group in Mosul / Iraq. Ann Tropical Med Public Health. 2019;22:136-45. DOI: https:// 10.36295/asro.2019.220815

  29. Guinault D, Del Bello A, Lavayssiere L, Nogier MB, Cointault O, Congy N, et al29. . Outcomes of kidney transplant recipients admitted to the intensive care unit: a retrospective study of 200 patients. BMC Anesthesiol. 2019;19(1):130. DOI: https:// 10.1186/s12871-019-0800-0

  30. D'Orsogna L, van den Heuvel H, van Kooten C, Heidt S, Claas FHJ. Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. Immunogenetics. 2017;69(8-9):631-41. DOI: https:// 10.1007/s00251-017-0989-3

  31. Krishnan NS, Zehnder D, Daga S, Lowe D, Lam FT, Kashi H, et al31. . Behaviour of Non-Donor Specific Antibodies during Rapid Re-Synthesis of Donor Specific HLA Antibodies after Antibody Incompatible Renal Transplantation. PLoS One. 2013;8(7):e68663. DOI: https:// 10.1371/journal.pone.0068663

  32. Ettenger R, Chin H, Kesler K, Bridges N, Grimm P, Reed EF, et al32. . Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation. Am J Transplant. 2017;17(6):1549-62. DOI: https:// 10.1111/ajt.14169

  33. Vilibic-Cavlek T, Kolaric B, Ljubin-Sternak S, Kos M, Kaic B, Mlinaric-Galinovic G. Prevalence and dynamics of cytomegalovirus infection among patients undergoing chronic hemodialysis. Indian J Nephrol. 2015;25(2):95-8. DOI: https:// 10.4103/0971-4065.139488

  34. Radhakrishnan R, Gopal B, Zachariah U, Abraham P, Mohapatra A, Valson A, et al34. . The long-term impact of hepatitis C infection in kidney transplantation in the pre-direct acting antiviral era. Saudi J Kidney Dis Transpl. 2018;29(5):1092-9. DOI: https:// 10.4103/1319-2442.243964

  35. Levitsky J, Doucette K. Viral hepatitis in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):147-68. DOI: https:// 10.1111/ajt.12108

  36. Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, et al36. . Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol. 2012;91(4):587-95. DOI: https:// 10.1007/s00277-011-1351-8

  37. Shoman S, Nabil M, Tabl A, Ghanem H, Kafrawy SE. Assessment of immunological changes in Epstein-Barr virus co-infection in Egyptian chronic HCV patients. Mem Inst Oswaldo Cruz. 2014;109(6):722-7. DOI: https:// 10.1590/0074-0276140049

  38. Rao SC, Ashraf I, Mir F, Samiullah S, Ibdah JA, Tahan V. Dual Infection with Hepatitis B and Epstein-Barr Virus Presenting with Severe Jaundice, Coagulopathy, and Hepatitis B Virus Chronicity Outcome. Am J Case Rep. 2017;18:170-2. DOI: https:// 10.12659/ajcr.901688

  39. Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, et al39. . The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91(8):1059-67.

  40. Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TM, Campos SV, et al40. . Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo). 2015;70(7):515-23. DOI: https:// 10.6061/clinics/2015(07)09

  41. Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, et al41. . Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2016;37(2):138-43. DOI: https:// 10.3760/cma.j.issn.0253-2727.2016.02.011




2020     |     www.medigraphic.com